george church
@geochurch
Professor @Harvard @MIT @PGorg @WyssInstitute tech dev: #CRISPR #NGS #BRAINi
E11 Bio is excited to share a major step towards brain mapping at 100x lower cost, making whole-brain connectomics at human & mouse scale feasible (🧠→🔬→💻). Critical for curing brain disorders, building human-like AI systems, and even simulating human brains. 1/N 🧵
One year ago: 600 bp Today: 50,000 bp We are now accepting early access orders for synthetic DNA up to 50 kb — delivered in <4 weeks. Build without limits and innovate without compromise with longer DNA: businesswire.com/news/home/2025…
Species-defining differences (governmental and scientific) include a mixture of physical & physiological measures, breeding/food/ecosystem preferences, and DNA. There is no magic number of changes in any of these categories. A single genetic change can cause speciation ... while…
We’re excited to announce that @Roche has exercised its option to license one of our next-generation AI-designed AAV vectors for neurological diseases! 🧬🚀 More on this key milestone for AI in gene therapy: businesswire.com/news/home/2025…
I’m thrilled to announce that the application for the 2025 edition of our @medialab and global synthetic biology course, “How to Grow (Almost) Anything” is now open! Application link in thread 👇
Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function.…
I’m thrilled to announce: at @jura_bio we’ve constructed a new kind of generative protein model, which allows us to manufacture its generated designs in the real world at petascale. Paper: static1.squarespace.com/static/66db3a5… Blog: jura.bio/blog/variation…
I’m speaking today at @PEGSboston, 5:10 pm, Eng Antibodies. Talk will cover new “solMPMP” tech from @nablabio where we use generative ML to create soluble proxies of valuable multipass membrane protein drug targets, and use these proxies to facilitate design of new biologics.
Excited to share @nablabio is partnering with 3 of the world’s largest pharma cos to use integrated AI and wet-lab tech to design antibodies against challenging disease targets. Thrilled to also add @radicalvcfund who led our $26M Series A to the family! bit.ly/4dDk4lP